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Hepatocellular  carcinoma  (HCC)  is  the  third  most  frequent  cause  of cancer  deaths through-
out the world.  This  study  was  aimed  to analyze  oxidative  stress  and  cell damage  in a
multistage  model  of  liver  carcinogenesis  induced  by diethylnitrosamine  (DEN)  in  rats.
Male  Wistar  rats  weighing  145–150  g were  divided  into  three  groups:  control,  precan-
cerous  lesions  (PL) (which  received  100  mg  DEN  once  a  week  every  6  weeks  up  to  28
weeks),  and  advanced  HCC  (50  mg DEN  once/twice  per week  up  to  19 weeks).  Lipid per-
oxidation  (TBARS),  superoxide  dismutase  (SOD)  activity,  and  expression  of  transforming
growth  factor-1  beta  (TGF)-1,  endothelial  and  inducible  nitric  oxide  syntahese  (eNOS,
iNOS),  NADPH  quinone  oxireductase  (NQO)-1,  nuclear  factor  erythroid  2-related  factor
(NrF)2, kelch-like  ECH-associated  protein  (Keap)1  and heat  shock  protein  (HSP)70  were
measured. TBARS  concentration  was  augmented  in the  PL  and  advanced  HCC  groups.  SOD
activity,  TGF-1  and Nrf2  expression  were  higher  in  animals  with  precancerous  lesions.eat shock protein In  advanced  HCC,  expression  of NQO1  and  iNOS  increased  while  there  was  a decrease  in
HPS70 expression.  Data  obtained  provide  evidence  for the  differential  activation  of pro-
teins  involved  in  oxidative  stress  and  cell  damage  during  progression  of carcinogenesis  in
an animal  model  of  HCC.
©  2014  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
the  CC  BY-NC-N
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The percentage of ﬁbrosis (%) in the liver tissue was
determined by morphometric measurements. Ten images334 A.J. Moreira et al. / Toxic
1. Introduction
The most common histological type of primary liver
cancer is hepatocellular carcinoma (HCC). In 2008, there
were approximately 694,000 deaths from HCC, making it
the third most common cause of cancer death worldwide
[1]. Chronic liver diseases are risk factors that predispose to
HCC, as any agent or factor that chronically and slowly dam-
ages the hepatocytes induces mitosis and makes the DNA of
these cells more susceptible to genetic alterations [2]. Such
diseases include alcoholic cirrhosis, hepatitis B or C virus
infection, 1-antitrypsin deﬁciency, hemochromatosis and
tyrosinemia. In HCV-positive patients, for example, HCC
appears on average 30 years after infection, almost exclu-
sively in those with cirrhosis [3]. The development of HCC
is a complex process, involving accumulation of genetic
and epigenetic alterations, which passes through stages
of initiation, promotion and progression, and numerous
experimental observations have shown that viral products
may  contribute to the malignant transformation of hepa-
tocytes [4].
Curative therapeutic approaches for HCC involve liver
transplantation, or surgical and radiofrequency ablation,
but these treatments are not yet effective [5]. Although
surgical resection can sometimes be curative, few patients
have resectable tumors because of the presence of cirrhosis
or distant metastases; moreover, even after resection, pre-
existing liver cirrhosis persists and may  cause other tumors
in the remaining tissue. Orthotopic liver transplantation is
the only truly curative therapy, although issues of recur-
rence and development of metastases remain. In case of
unresectable tumor, treatment is limited, as HCC does not
respond to chemotherapy and the liver does not tolerate
high doses of radiotherapy [6].
HCC carries a high mortality rate and patients with
chronic liver diseases usually take a long time before
HCC occurs. Therefore, early diagnosis of HCC in precan-
cerous lesions may  improve the outcome of treatment,
and it is necessary to encourage basic research to bet-
ter understand the pathogenesis of this disease. Many
experimental animal models of hepatocarcinogenesis have
been described over the last decades. The most widely
accepted, proposed by Farber et al. [7], combines chemical
induction by diethylnitrosamine (DEN) with partial hepa-
tectomy. Since then, DEN has been used to initiate the liver
cancer either alone or in combination with other carcino-
gens [8–11]. However, fewer studies have characterized in
detail the temporal evolution of oxidative stress and cell
damage implicated in hepatocarcinogenesis. Understand-
ing changes from pre-neoplastic to carcinoma lesions in
oxidative stress, inﬂammation and liver ﬁbrosis could be
important to improve the knowledge on the transition of
chronic inﬂammatory liver diseases to HCC. In the current
study, we used a multistage model of chronic and inter-
mittent exposure to DEN without partial hepatectomy to
get insight into changes in markers of cell damage dur-
ing progression of the disease. Two different protocols of
drug exposure (designed to induce advanced HCC and pre-
cancerous lesions) allowed us to study effects of time on
tumor onset, liver pathology, blood chemistry, and markers
of oxidative stress and cell damage in the liver.ports 2 (2015) 333–340
2. Materials and methods
2.1. Animals and procedures
Male Wistar rats weighing 145–150 g were used for this
study and were obtained from the Central Animal Labo-
ratory of the Federal University of Pelotas, Rio Grande do
Sul (Brazil). The rats were caged at 24 ◦C, under a 12-h
light–dark cycle and with free access to food and water until
the time of the experiments at the Animal Experimentation
Division of Hospital de Clínicas de Porto Alegre (Brazil). All
experiments were performed in accordance with the Guid-
ing Principles for Research Involving Animals (NAS) under
protocol number 120355.
The animals were divided into three groups: CO: control,
precancerous lesions (PL) and advanced HCC. Animals in
the PL group were given diethylnitrosamine (DEN, Sigma
Aldrich, St. Louis, MO)  at a dose of 100 mg/kg body weight
i.p. once a week every 6 weeks up to 28 weeks. Animals in
the advanced HCC group received DEN at a dose of 50 mg/kg
body weight i.p. twice a week for the ﬁrst three weeks and
once a week from weeks 4 to 6 and 11 to 13 up to 19 weeks.
A single dose of 2-acetylaminoﬂuorene (2-AAF, 100 mg/kg,
Sigma–Aldrich, St. Louis, MO)  was administered in week 4
to both DEN groups.
Following a 12-h fast, the animals were anesthetized
with ketamine hydrochloride (Ketalar®, 100 mg/kg – Pub-
Chem CID: 15851) and xylazine (50 mg/kg – PubChem CID:
5707) and subjected to blood collection for measurement
of biochemical parameters.
Samples of livers for histology, biochemical and molec-
ular analyzes were taken from the same lobe (right medial
lobe). The collected sample was  withdrawn from the area
where the nodules were visible. The animals were killed at
the end of the experiment by exsanguination under deep
anesthesia, as described in the American Veterinary Medi-
cal Association (AVMA) Guidelines on Euthanasia [12].
2.2. Biochemical analysis
Serum levels of alanine aminotransferase (ALT) (U/L),
aspartate aminotransferase (AST) (U/L) were determined
by kinetic UV test. Gamma-glutamyl transferase (gamma-
GT) (U/L), and alkaline phosphatase (AP) (U/L) were
quantiﬁed by colorimetric kinetic test. They were mea-
sured using routine laboratory methods of the Hospital de
Clínicas de Porto Alegre by enzymatic method (automated
– Siemens Advia 1800 Chemistry system).
2.3. Histology
For histological examination, a specimen of liver was
trimmed and ﬁxed by immersion in 10% buffered formalin
for 24 h. The blocks were dehydrated in a graded ethanol
series and embedded in parafﬁn wax. Serial 3-m sections
were stained with hematoxylin and eosin and picrosirius
red.from each slide were captured from randomly selected
high-power ﬁelds (200× magniﬁcation) containing the
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onjunctive tissue area positive. Morphometric assessment
f the percentage of the ratios of conjunctive tissue relative
o whole liver were performed using the Adobe Photoshop
S5 Extended 10.0 (Adobe Systems, San Jose, CA), according
o the protocol described by Souza et al. [13].
.4. Lipid peroxidation and cytosolic superoxide
ismutase (SOD)
The livers were excised, weighed, and immediately
rozen at −70 ◦C. Frozen tissue from each rat was  homoge-
ized in ice-cold phosphate buffer (KCl 140 mM,  phosphate
0 mM,  pH 7.4) and centrifuged at 3000 rpm for 10 min.
rotein concentration in the liver homogenates was
etermined using a bovine albumin solution [14]. Lipid
eroxidation was determined by measuring the concentra-
ion of TBARS (nmol/mg protein) [15]. Spectrophotometric
bsorbance was determined in the supernatant as 535 nm.
ytosolic SOD (EC 1.15.1.1) was assayed as described by
isra and Fridovich [16].
.5. Western blot
Western blot analysis was performed on cytosolic
xtracts prepared by liver tissue homogenization in
40 mM NaCl, 15 mM EDTA (PubChem CID: 6049), 20 mM
lycerol (10%), and a protease inhibitor cocktail [17].
he mixture was incubated on ice for 30 min  and
entrifuged for 30 min  at 12,000 g and 4 ◦C. The super-
atant fraction was collected and stored at −80 ◦C in
liquots until use. Protein concentration was measured
y the Bradford assay [14]. Samples containing 50–100 g
f protein were separated by sodium dodecylsulfate-
olyacrylamide gel electrophoresis (9–12% acrylamide)
nd transferred to polyvinylidene ﬂuoride (PVDF) mem-
ranes [18,19]. The membranes were then blocked with
% nonfat dry milk in Tris-buffered saline containing
.05% Tween 20 (TTBS) for 1 h at room temperature and
robed overnight at 4 ◦C with polyclonal anti-TGF-1
SC31609/25 kDa), anti-eNOS (SC8311/140 kDa), anti-iNOS
SC7271/130 kDa), anti-NQO1 (SC376023/32 kDa), anti-
eap1 (SC 33569/69 kDa), and anti-Nrf2 (SC30915/57 kDa)
ntibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
t 1:200–1:1000 dilution with TTBS in 5% nonfat dry milk,
nd anti-HSP70 (H5147/73 and 72 kDa) (Sigma–Aldrich, St.
ouis, MO,  USA) antibody at 1:5000 dilution with TTBS in 5%
onfat dry milk, and anti-GAPDH (G9545/37 kDa) antibody
Sigma–Aldrich, St. Louis, MO,  USA) antibody at 1:1000
ilution with TTBS in 5% nonfat dry milk. After washing
ith TTBS, the membranes were incubated for 1 h at room
emperature with secondary HRP-conjugated antibody
Dako, Glostrup, Denmark, 1:4000). Protein detection was
erformed via chemiluminescence using a commercial ECL
it (Amersham Pharmacia Biotech, Little Chalfont, Great
ritain) [20]. The density of the speciﬁc bands was quanti-
ed with an L-Pix Chemi Molecular Imaging densitometer..6. Statistical analysis
Means and standard deviations (SD) were calculated
or all data. Signiﬁcant differences between means wereports 2 (2015) 333–340 335
evaluated by one-way analysis of variance (ANOVA). In
the case of signiﬁcance, Tukey’s test was  applied. P values
<0.05 were deemed signiﬁcant. All analyses were carried
out using SPSS 18.0.
3. Results
3.1. Body weight and blood biochemical analyses
Rats with advanced HCC showed a slower growth rate
than the PL and control animals, reaching at the time of
sacriﬁce a body weight approximately 30% lower than that
of controls, with a signiﬁcant increase in the hepatosomatic
ratio (Table 1). Blood analyses indicated that AST, ALT, AP
and GGT levels were signiﬁcantly higher in the advanced
HCC group compared to control rats. Enzyme levels for the
PL group also differed from those in control rats, although
values were lower than those in the HCC group (Table 1).
3.2. Histology and morphometric study
The liver histology of animals in the advanced HCC
group was characterized by chronic damage and areas of
cellular atypia such as large nucleoli, increased nucleus to
cytoplasm ratio and increased mitotic index at 19 weeks.
The signs observed included lymphocytic inﬁltration, cells
with enlarged nuclei, extremely atypical hepatocytes. Loss
of normal hepatic parenchyma was present, with a pseudo-
acinar and trabecular growth pattern. Moderate and large
nodules were present (20% and 80% of rats, respectively)
[21]. Animals in the group with precancerous lesions had
developed early-stage HCC or preneoplastic lesions at 28
weeks. The liver histology in this group was  consistent with
multiple nodules of regeneration (small nodules in 100%
of animals) and preneoplastic foci (Fig. 1). Distorted lobu-
lar architecture was  also observed, with increased mitotic
index and hepatocellular damage such ﬁbrosis and cirrho-
sis. The cytologic criteria included nuclear and cytoplasmic
changes, multinucleation, centrally located nuclei, promi-
nent nucleoli and increased cell density [22].
The percentage of ﬁbrosis in the liver tissue was
determined by morphometric measurement of picrosirius
red-stained samples. Data obtained indicate that the extent
of ﬁbrotic tissue increased slightly in rats with precan-
cerous lesions and augmented markedly in animals with
advanced HCC (control: 1.7 ± 0.1; precancerous lesions:
3.8 ± 1.5; advanced HCC: 12.3 ± 2.9; p < .05).
3.3. Markers of lipid peroxidation and SOD activity
Determination of lipid peroxidation in liver tissue was
performed by the TBARS method, which showed a sig-
niﬁcant increase of malondialdehyde formation in both
groups of DEN-treated rats. TBARS increased by 81% in the
PL group when compared to control animals, while rats
with advanced HCC had values approximately 25% lower
than that of PL group. Liver activity of the antioxidant
enzyme SOD was signiﬁcantly increased in PL rats (+13%)
and reduced in the advanced HCC group (−32%) when com-
pared to control animals (Table 1).
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Table  1
Effects of advanced HCC and precancerous lesions on body weight, hepatosomatic ratio, serum levels of AST, ALT, AP and GGT, hepatic TBARS and liver SOD
activity.
Control Advanced HCC Precancerous lesions
Initial weight (g) 146 ± 6 147 ± 7 154 ± 6
Final weight (g) 486 ± 8 323 ± 53a 437 ± 26b
HSR (%) 3.1 ± 0.2 12.4 ± 6.6a 3.5 ± 0.4b
AST (U/L) 102 ± 10 238 ± 70a 160.5 ± 15a,b
ALT (U/L) 49 ± 4 160 ± 27a 71 ± 7a,b
AP (U/L) 71 ± 12 249 ± 84a 141 ± 57a,b
GGT (U/L) 2.2 ± 0.9 113.8 ± 6.6a 10.2 ± 1.7a,b
TBARS (nmol/mg prot) 0.11 ± 0.02 0.16 ± 0.03a 0.20 ± 0.02a
SOD (U SOD) 12.7 ± 0.4 8.7 ± 1.8a 15.9 ± 2.0a,b
Values are expressed as means ± SD for 8–10 rats. HSR, hepatosomatic ratio; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AP, alkaline
phosphatase; GGT, gamma-glutamyl transferase.
a p < .05 vs. control.
b p < .05 vs. advanced HCC.
3.4. TGF-1ˇ, Keap-1, Nrf2, NQO1, eNOS, iNOS and HSP70
expression
To evaluate the effects of early and advanced HCC
on development of ﬁbrosis, the expression of TGF-1
was quantiﬁed by measurement of protein expression.
Both PL and advanced HCC animals exhibited a signiﬁ-
cant induction of TGF-1,  which reached a higher extent
in the ﬁrst group (+98%) (Fig. 2). Concerning markers
Fig. 1. Photomicrographs of liver sections. Left panels: tissue samples counter st
(B)  Advanced HCC: non-cancerous cells (a) and atypical hepatocytes (b). Abnorm
growth pattern. (C) Precancerous lesions: low-grade dysplastic nodules (DN) an
panels:  tissue samples counter stained with picrosirius red. (D) Control: normal
Precancerous lesions: moderated deposits of ﬁbrosis (Original magniﬁcation 100of inﬂammation, eNOS expression was reduced (−60%),
whereas iNOS expression increased strongly in animals
with advanced HCC (Fig. 2). Protein markers related to
oxidative stress were also evaluated. The advanced HCC
group exhibited a signiﬁcant induction of NQO1 protein
as compared with the control group (+82%). Rats in the
PL group overexpressed nuclear factor Nrf2 (+260%), while
in the advanced HCC group Nrf-2 expression was  reduced
(−56%) and Keap-1 was markedly overexpressed (+308%).
ained with hematoxylin-eosin. (A) Control: normal hepatic parenchyma.
al hepatic parenchyma was present, with a pseudo-acinar and trabecular
d collagen deposition (black arrows) (Original magniﬁcation 40×). Right
 hepatic parenchyma. (E) Advanced HCC: intense deposits of ﬁbrosis. (F)
×).
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Fig. 2. Western blot analysis of TGF-1,  eNOS, and iNOS. Protein from
liver extracts was separated by sodium dodecylsulfate-polyacrylamide gel
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Fig. 3. Western blot analysis of NQO1, Keap1, Nrf2, HP73 and HP72.
Protein from liver extracts was separated by sodium dodecylsulfate-
polyacrylamide gel electrophoresis followed by immunoblotting. (A)lectrophoresis followed by immunoblotting. (A) Representative images.
B)  Densitometric quantiﬁcation. Values are expressed as means ± SD
n  = 5). ap < .05 vs. control, bp < .05 vs. advanced HCC.
xpression of the main isoforms of the HSP family (con-
titutive HSP 73 and stress-inducible HSP72) decreased
igniﬁcantly in animals with advanced HCC (−32% and
74%, respectively) (Fig. 3).
. Discussion
This study provides evidence of the activa-
ion/inhibition of different proteins involved in oxidative
tress and cell damage in a multistage animal model of
epatic carcinogenesis. Blood chemistry, liver histology,
arkers of oxidative stress and expression of different
roteins related to HCC pathogenic mechanisms were
easured in rats with early/precancerous lesions (PL) or
ate-stage HCC reached through different protocols of DEN
dministration.
DEN is a potent hepatocarcinogenic agent [23], which
s hydrolyzed to nitrosamine, generating an electrophilic
adical. The rats that were exposed most frequently to low
oses of DEN had developed advanced HCC at 19 weeks,
hereas animals exposed to high doses on fewer occa-
ions developed preneoplastic lesions or early HCC by 28
eeks. In addition, we used 2-AAF on week 4 to inhibit
he proliferation of normal hepatocytes [8,24]. With this
esign, HCC was already established by weeks 17–19 in
he advanced HCC group, suggesting that the therapeutic
indow to address inﬂammation occurs on week 4 or 5,
hereas cirrhosis is established by weeks 10–12.
Aminotransferase levels were signiﬁcantly increased
n the advanced HCC group. By week 19, there was  anRepresentative images. (B) Densitometric quantiﬁcation. Values are
expressed as means ± SD (n = 5). ap < .05 vs. control, bp < .05 vs. advanced
HCC.
elevation of both ALT and AST, indicative of liver injury
and hepatocellular damage [25], reaching values similar
to those previously reported in other models of progres-
sive cirrhosis induced in rat by repeated injections of DEN
[9,26]. Furthermore, AP was elevated concomitantly with
a signiﬁcant increase in the GGT level, which indicates the
presence of obstructive and cholestatic disease. After anal-
ysis of the dimensions of the masses found, we  believe that
tumor nodules caused compression of the hepatic ducts.
Both ALP and GGT have been conﬁrmed as useful factor for
conﬁrmation of stages in HCC [10], and it is known that
elevated GGT associates with increased cancer risk [27,28],
seeming to be involved in the activation of pro-oncogenes
or the inactivation of tumor-suppressor genes [29].
The effects of HCC stages on development of ﬁbrosis
were evaluated by quantifying TGF-1  expression and per-
centage of ﬁbrosis (%). TGF-1 was  signiﬁcantly increased
in all rats with precancerous lesions, while the intense
deposits of ﬁbrosis was  more prominent in animals with
advanced HCC. This result may  suggest that the TGF-1 is
ﬁrst activated in the early stage of HCC. Due to this activa-
tion, stellate cells (HSC) respond with intense deposits of
ﬁbrosis observed in the late stage of HCC. A strong associa-
tion exists between ﬁbrosis and HCC, because TGF-1 is an
important peptide mediator of hepatic stellate cells (HSC),
which activate and stimulate matrix synthesis, leading to
progressive liver failure [30]. A wealth of evidence suggests
the existence of reciprocal signaling and positive feed-
back loop between precancerous hepatocytes and stellate
cells. This cycle enhances the growth of hepatocytes and
HSC activation, which promotes carcinogenesis by altering
the stromal environment and promoting angiogenesis.
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Furthermore, the accumulation of extracellular matrix
would lead to increased proliferation and decreased apo-
ptosis, favoring carcinogenesis [31]. TGF-1  signaling in
carcinogenesis is complex; in early-stage HCC, it acts as a
tumor suppressor, but in the late phase it plays a role as a
tumor promoter [61].
We  also studied the behavior of the inﬂammatory
mediator nitric oxide (NO), evaluating eNOS and iNOS
expression in cytoplasmic extract of livers with advanced
HCC and precancerous lesions. iNOS expression was
increased in advanced HCC, whereas eNOS expression
decreased signiﬁcantly. Hanahan and Weinberg [32,33]
have proposed six biological hallmarks necessary for tumor
development, Overexpression of iNOS acts on three of these
six markers. This occurs when overexpressed iNOS inter-
acts on two important molecular pathways, IKK/NF-kappaB
and RAS/ERK. Activation of these pathways triggers the
transcription of genes that control cell growth, angiogen-
esis, and inhibition of cell death [34,35]. Regarding the
role eNOS in carcinoma, Decker et al. [36] demonstrated
that eNOS overexpression was associated with fewer and
smaller tumor lesions as well as increased animal survival.
However, eNOS−/− knockout animals developed larger
tumors and had worse survival. This vascular dysfunction
in chronic liver disease is an important sign that precedes
carcinoma [36].
After determination of proteins classically involved in
chronic liver diseases, we assessed oxidative stress, by
measuring the cytosolic concentration of TBARS and quan-
tifying SOD activity. TBARS was already increased in the
PL groups compared to controls. DEN is hydrolyzed in
nitrosamine, generating the ethyl radical, responsible for
an increase in intensiﬁcation of oxidative stress. Many
studies have linked oxidative stress to pathogenesis and
disease prognosis [37–39]. One of the key factors in car-
cinogenesis is an imbalance of the redox state, favoring
the formation of several toxic products such as malondi-
aldehyde and 4-hydroxynonenal, which can attack lipids,
proteins and DNA, leading to carcinogenicity and muta-
genicity [40,41]. In this study, SOD activity was reduced in
advanced HCC, whereas increased in early HCC, signaling
the presence of the superoxide anion. Similar results, show-
ing increases in oxidative stress and reduction in SOD levels
in animals with HCC have been previously reported, indi-
cating that the decrease of SOD activity intensiﬁes with the
disease progression [8,42].
In addition to SOD activity, NQO1 expression was  also
determined. While SOD activity was signiﬁcantly reduced
in animals with advanced HCC, NQO1 protein expression
increased signiﬁcantly. Most solid tumors express high lev-
els of NQO1 [43], and biochemical studies have shown that
NQO1 is induced by numerous chemicals, including poly-
cyclic aromatic hydrocarbons and azo dyes. Two  regulatory
elements responsible for the NQO1 gene are the antioxi-
dant response element (ARE) and the xenobiotic response
element (XRE) [44]. According to Venugopal and Jaiswal
[45] an increase in NQO1 expression occurs in response
to the generation of ROS caused by inﬂammation or xeno-
biotic exposure. Conversely, precancerous lesions showed
augmented SOD activity with no increase in NOQ1 pro-
tein expression. These ﬁndings suggest that NQO1 actsports 2 (2015) 333–340
directly as a superoxide anion scavenger, although less efﬁ-
ciently than SOD [46]. Its lack results in additional loss
of protection against oxidative stress, exposing the cell to
the aggressions of ROS. Tissues with high SOD levels and
low NQO1 expression may  have decreased clearance of
superoxide anion, generating other reactive species and
worsening liver injury [47].
In this study, Keap1/Nrf2 were assessed in animals with
PL and advanced HCC. There is doubt as to whether Nrf2 is
a tumor suppressor or oncogenic [48]. Under basal con-
ditions, Nrf2 is sequestered in the cytoplasm by Keap1,
but induction of oxidative stress is able to dissociate Nrf2
from Keap1, leading to its translocation to the nucleus and
subsequent increase on antioxidant genes expression [49].
We observed that animals in late-stage (advanced) HCC
showed Keap1 overexpression and Nrf2 downregulation
compared to animals in the PL group. It is known that the
Nrf2 system could be induced by chemical carcinogens [50].
Activation of this factor facilitates cytoprotection and con-
tributes to the proliferation and survival of tumor cells,
whereas its inhibition results in degradation [51,52], allow-
ing an increase in ROS attacks to the cell. The role of Nrf2 is
dependent on the stage of carcinogenesis. In the inﬂamma-
tory phase, with precancerous lesions, increased activation
of Nrf2 aims to reduce oxidative stress, thus contributing
to tumor suppression [53]. Meanwhile, maintaining Nrf2
activation during the tumorigenesis stage may  facilitate the
transformation of dysplastic nodules into malignant cancer
cells and make them resistant to treatment [53,54]. During
the development of carcinoma, an increase in Nrf2 protein
is associated with poor prognosis [48]. In our work, Nrf2
and Keap1 changes observed in both PL and HCC groups
were in parallel with the changes on SOD activity, con-
tributing to liver injury during hepatocarcinogenesis.
Another interesting ﬁnding from our investigation was
the signiﬁcant reduction in the expression of HSP70 in
liver tissue with advanced HCC. HSP70 has strong cyto-
protective effects and functions as a molecular chaperone
in protein folding, transport, and degradation [55]. HSP70
downregulation is associated with carcinogenesis of the
oral epithelium, and is a marker of HCC [56]. HSP70 down-
regulation also correlates with poor prognosis in breast
cancer [57], endometrial cancer [58], and pancreatic cancer
[56]. Rohde et al. [59] reported that HSP70 is not a condition
for the growth of tumor cells, but plays an important role in
maintaining the deregulated tumor cell cycle. Chuma et al.
[60] evaluated the expression of HSP70 in liver tissue with
and without cancer, and identiﬁed HSP70 as a molecular
marker of HCC progression.
In conclusion, we  have shown a multistage induction of
HCC in rats through chronic and intermittent exposure to
carcinogenic agents. Changes in SOD and NrF2 and TGF-1
stand out as markers of oxidative stress and cell damage
in early HCC. TGF-1 stimulates extracellular matrix for-
mation and contributes to cell proliferation, SOD and Nrf2
overexpression act as cytoprotectives factors in precancer-
ous lesions. In advanced HCC, however, there is a decreased
expression of HSP70, and an increase in the expression
of NQO1 and iNOS, that interact with important genes
controlling cell growth, angiogenesis and apoptosis. These
results conﬁrm that oxidative stress and ﬁbrosis plays an
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